Borregaard ASA
BRG.OL
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.05B
Close$
$94.04
36.7% downside
Current Fair Value
36.7% downsideOvervalued by 36.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.05 Billion |
|---|---|
| Enterprise Value | $17.19 Billion |
| Dividend Yield | $4.75 (3.15%) |
| Earnings per Share | $6.22 |
| Beta | 0.56 |
| Outstanding Shares | 100,000,000 |
Return
| Return on Equity | 3.01% |
|---|---|
| Return on Assets | 1.77% |
| Return on Invested Capital | 14.79% |
Valuation & Multiples
| P/E Ratio | 88.82 |
|---|---|
| PEG | -59.29 |
| Price to Sales | 1.93 |
| Price to Book Ratio | 2.65 |
| Enterprise Value to Revenue | 2.22 |
| Enterprise Value to EBIT | 15.15 |
| Enterprise Value to Net Income | 102 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.41 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 16, 2026
EPS Estimate
$0.86
Average shareholder expectationRevenue Estimate
$1.90 B
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$2.13
Average shareholder expectationRevenue Estimate
$1.95 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Borregaard ASA
1,228 employees
CEO: Tom Erik Foss-Jacobsen Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMa...